Uccc-Gi-20-02
Posted Date: May 6, 2021
- Investigator: Davendra Sohal
- Specialties: Cancer, Oncology, Pancreatic Cancer
- Type of Study: Drug
The purpose of this study is to determine if neoadjuvant therapy to increases resection rate for pancreatic adenocarcinoma. Chemotherapy will begin with FOLFIRINOX - a standard regimen used in pancreatic cancer treatment, consisting of 5-fluorouracil, irinotecan and oxaliplatin. Patients will undergo radiation therapy if recommended. Pancreatectomy should occur within 4 to 8 weeks after the last dose of preoperative chemotherapy
Criteria:
Diagnosis Of Pancreatic Carcinoma Or Adenocarcinoma Confirmed By Tissue, Resectable Or Borderline Resectable Primary Tumor, Ecog 0-1, Adequate Organ And Marrow Function As Defined In Protocol, No Uncontrolled Intercurrent Illness Or Comorbidities That Would, In The Opinion Of The Treating Physician, Prevent Receipt Of Standard Of Care Chemotherapy, Radiation Or Surgery.
Keywords:
Pancreatic Cancer, Adenocarcinoma
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com